Continuously Infused Intracerebral (IC) Recombinant-Methionyl Human Glial Cell Line-Derived Neurotrophic Factor (r-metHuGDNF) for the Treatment of Idiopathic Parkinson's Disease

PHASE1CompletedINTERVENTIONAL

Timeline

Start Date

Not specified

Conditions

Parkinson Disease

Interventions

DRUG

recombinant-methionyl human glial cell line-derived neurotrophic factor

Trial Locations (1)

Department of Neurology, New York

All Listed Sponsors

lead

National Center for Research Resources (NCRR)

NIH